Completed PHASE1 INTERVENTIONAL 4-arm NCT01397604

The Effects of GLA on Human Volunteers

A Randomized, Blinded, Placebo-Controlled Phase 1 Study to Evaluate the Safety and Immunogenicity of GLA in Healthy Volunteers

Sponsor: IDRI Corporation

Conditions Healthy Volunteers

Interventions GLA-AF GLA-SE Squalene

Updated 7 times since 2017 Last updated: Sep 19, 2013 Started: Jul 31, 2011 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy Volunteers and is currently completed. IDRI Corporation leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2024 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jan 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

IDRI Corporation
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Rockefeller University

Data source: Rockefeller University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States